Deep Dive: The Gold Rush to Cure the Obesity Epidemic
GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapidly growing market for these drugs, projected to expand from $22 billion to over $100 billion, driven by their effectiveness without requiring major lifestyle changes. We explore the competition sparked by supply shortages, with companies like Hims offering affordable alternatives, and discuss innovations like pill…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.